These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34405547)

  • 21. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Drug Protects Against Myelosuppression Secondary to Lung Cancer Chemotherapy.
    Aschenbrenner DS
    Am J Nurs; 2021 Jun; 121(6):21. PubMed ID: 34009159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
    Lyman GH; Kuderer NM; Aapro M
    Front Oncol; 2021; 11():697908. PubMed ID: 34307165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trilaciclib: First Approval.
    Dhillon S
    Drugs; 2021 May; 81(7):867-874. PubMed ID: 33861388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics and exposure-response of trilaciclib in extensive-stage small cell lung cancer and triple-negative breast cancer.
    Li C; Rich B; Bullock JM; Barrière O; Marier JF; Beelen A
    Br J Clin Pharmacol; 2023 Mar; 89(3):1067-1079. PubMed ID: 36180417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
    Nagel S; Kellner O; Engel-Riedel W; Guetz S; Schumann C; Gieseler F; Schuette W
    Clin Lung Cancer; 2011 Jan; 12(1):62-9. PubMed ID: 21273182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
    Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest.
    Balducci L; Falandry C; List A
    Drugs Aging; 2023 Mar; 40(3):263-272. PubMed ID: 36715830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
    Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings.
    Goldschmidt J; Monnette A; Shi P; Venkatasetty D; Lopez-Gonzalez L; Huang H
    Future Oncol; 2022 Nov; 18(35):3881-3894. PubMed ID: 36377828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer.
    Li C; Horton JK; Sale M; Curd L; Goti V; Tao W; Beelen A
    Clin Drug Investig; 2022 Aug; 42(8):679-692. PubMed ID: 35842567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations.
    Kreys ED; Kim TY; Delgado A; Koeller JM
    J Oncol Pract; 2014 May; 10(3):168-73. PubMed ID: 24839275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
    Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.
    Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
    Oncol Rep; 2001; 8(4):861-6. PubMed ID: 11410799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.
    Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
    Am J Clin Oncol; 2000 Jun; 23(3):278-82. PubMed ID: 10857893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
    Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.